Most Read Articles
Dr. Joseph Delano Fule Robles, 12 Feb 2019

A team of investigators from the University of Hong Kong (HKU) identified high-risk Epstein Barr virus (EBV) variants present in 97 percent of nasopharyngeal carcinoma (NPC) cases.

4 days ago
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 23 Aug 2018
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.

Rifabutin triple therapy safe, effective in patients with multidrug-resistant strains of H. pylori

16 Jan 2018

No standard currently exists for the growing number of patients with multidrug-resistant strains of Helicobacter pylori, but a recent study has shown the safety and reliability of a 12-day low-dose rifabutin/high-dose proton pump inhibitor (PPI) regimen in patients infected with triple-resistant strains.

Of the 756 patients enrolled in the study, 254 were infected with a triple-resistant H. pylori strains after at least one antibiotic therapy course. In total, 213 of the infected participants had benefitted from the therapy, corresponding to a cure rate of 82.9 percent (95 percent CI, 78.3‒87.5) by intention-to-treat analysis and 88.7 percent (84.7‒92.7) at per-protocol analysis.

Furthermore, multivariate analyses showed no factor that independently predicted bacterial eradication.

In a study involving the Korean population, researchers found that rifabutin-based high-dose PPI‒combined therapy as empirical rescue treatment was more effective than rifabutin-based standard-dose PPI‒combined therapy, as well as safe and well tolerated in third-line treatment. [Helicobacter 2014;19:455-461]

In this study that evaluated the efficacy of 12-day rifabutin-based triple therapy, the investigators enrolled consecutive patients with dyspeptic symptoms after at least one antibiotic therapy course for H. pylori infection harbouring triple-resistant (clarithromycin, metronidazole, levofloxacin) strains.

Participants received triple therapy with esomeprazole 40 mg bid, amoxicillin 1 g bid and rifabutin 150 mg od for 12 days. Those who failed rifabutin therapy were empirically treated based on the judgment of the treating physician.

“Eradicating Helicobacter pylori continues to be a challenge, and no treatment regimen is uniformly successful in all treated patients,” the investigators said. “Triple therapy with rifabutin and amoxicillin is a successful rescue therapy after consecutive treatment failures.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 12 Feb 2019

A team of investigators from the University of Hong Kong (HKU) identified high-risk Epstein Barr virus (EBV) variants present in 97 percent of nasopharyngeal carcinoma (NPC) cases.

4 days ago
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pearl Toh, 23 Aug 2018
Restoration of CD4/CD8 ratio on combination antiretroviral therapy (cART) was associated with decreased risk of Kaposi sarcoma (KS) while baseline CD8 count was related to non-Hogkin lymphoma (NHL) risk in people living with HIV (PLHIV) who had achieved viral suppression on cART, according to the COHERE* study presented at the AIDS International Conference (AIC) 2018.
Roshini Claire Anthony, 16 Jan 2019

A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.